• Signed a definitive agreement to acquire dermatology and oral solids businesses from Sandoz Inc., USA.
  • Signed a definitive agreement to acquire Apotex Inc’s commercial operations in 5 European countries.
  • Started filing Oncology & Hormones, Dermatology and Nasal ANDAs in US.
  • Acquired Generis in Portugal – Focus on differentiated technology platforms and Specialty Pharmaceuticals.
  • Acquired four cell-culture derived biosimilar products from TL Biopharmaceutical AG.